These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 18635756)

  • 41. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 42. Antihyperuricemic properties of amflutizole in gout.
    Wortmann RL; Ridolfo AS; Lightfoot RW; Fox IH
    J Rheumatol; 1985 Jun; 12(3):540-3. PubMed ID: 3900392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia.
    Wang C; Yu Q; Jiang X; Deng Y; Sun F; Li X; Tao Y; Lin P; Ma Y; Zhu Y; Li C; Cao Y
    J Clin Pharmacol; 2023 Feb; 63(2):239-249. PubMed ID: 36131360
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
    Stack AG; Han D; Goldwater R; Johansson S; Dronamraju N; Oscarsson J; Johnsson E; Parkinson J; Erlandsson F
    J Clin Endocrinol Metab; 2021 Apr; 106(5):e2347-e2356. PubMed ID: 33075806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
    Schumacher HR; Becker MA; Lloyd E; MacDonald PA; Lademacher C
    Rheumatology (Oxford); 2009 Feb; 48(2):188-94. PubMed ID: 19141576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Febuxostat: drug review and update.
    Grewal HK; Martinez JR; Espinoza LR
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):747-58. PubMed ID: 24684266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
    Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
    Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Febuxostat versus allopurinol for gout.
    Lustberg ME
    N Engl J Med; 2006 Apr; 354(14):1532-3; author reply 1532-3. PubMed ID: 16598054
    [No Abstract]   [Full Text] [Related]  

  • 51. Febuxostat: a new treatment for hyperuricaemia in gout.
    Edwards NL
    Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
    Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
    Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics/pharmacodynamics of Y-700, a novel xanthine oxidase inhibitor, in rats and man.
    Yamada I; Fukunari A; Osajima T; Kamezawa M; Mori H; Iwane J
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1123-5. PubMed ID: 15571214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Febuxostat (Teijin/Ipsen/TAP).
    Tomlinson B
    Curr Opin Investig Drugs; 2005 Nov; 6(11):1168-78. PubMed ID: 16312139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
    Khosravan R; Grabowski B; Wu JT; Joseph-Ridge N; Vernillet L
    Br J Clin Pharmacol; 2008 Mar; 65(3):355-63. PubMed ID: 17953718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The xanthine oxidase inhibitor Febuxostat reduces tissue uric acid content and inhibits injury-induced inflammation in the liver and lung.
    Kataoka H; Yang K; Rock KL
    Eur J Pharmacol; 2015 Jan; 746():174-9. PubMed ID: 25449036
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.
    Kamel B; Graham GG; Williams KM; Pile KD; Day RO
    Clin Pharmacokinet; 2017 May; 56(5):459-475. PubMed ID: 27753003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
    Naik H; Wu JT; Palmer R; McLean L
    Br J Clin Pharmacol; 2012 Aug; 74(2):327-35. PubMed ID: 22242967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Are dosing adjustments required for colchicine in the elderly compared with younger patients?
    Wason S; Faulkner RD; Davis MW
    Adv Ther; 2012 Jun; 29(6):551-61. PubMed ID: 22753019
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modeling and Simulation for Estimating the Influence of Renal Dysfunction on the Hypouricemic Effect of Febuxostat in Hyperuricemic Patients Due to Overproduction or Underexcretion of Uric Acid.
    Hirai T; Kimura T; Echizen H
    Biol Pharm Bull; 2016; 39(6):1013-21. PubMed ID: 27251504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.